"We have had the pleasure of continuously working with the team at Rx Communications since immediately after our IPO in 1996. 16-years later, we still rely on them for key strategic counsel, market intelligence, investor outreach and communication. Through the peaks and valleys of our corporate growth, Rx has been by our side, helping to build our institutional shareholder base from just 30% when we began working together, to approximately 90% today. The firm offers consistent, sage advice, critical investment community contacts and, above all, commitment. We are very pleased with our long-standing relationship with the firm."

• Dr. Leonard Bell, Chief Executive Officer
  Alexion Pharmaceuticals, Inc.

"I have worked with the Rx Communications team for approximately 18 years. From our days as a garage start-up, pioneering the life science real estate niche, through our IPO on the NYSE and continued growth into a multi-billion dollar company and the leader in our industry -- Rx has been a critical advisor. We consider them members of our team, as they have worked side-by-side with us, providing counsel and helping to improve and expand our visibility and institutional ownership base. Our investors often comment on their professionalism and value, and we look forward to working with their high caliber team for years to come."

• Joel S. Marcus, Chairman, Chief Executive Officer and Founder
  Alexandria Real Estate Equities, Inc.

"We have been working with Rx Communications Group for two years now and we regard them as a trustworthy partner with excellent knowledge specifically targeted to our needs and those of our shareholders.  Working with Rx is always a joy."

• Peter Nielsen, President and Chief Executive Officer
  Bio-Path Holdings, Inc.

"Providing only senior level counsel, Rx Communications is unique among today’s IR agencies. The firm is detail oriented and laser focused on the end goal. Their counsel and support has been instrumental over the years, as they have helped Catalyst to educate the market on its value proposition, and as they have helped us navigate through several difficult situations surrounding our ongoing product development."

• Patrick J.  McEnany, Co-Founder, Chairman, President and Chief Executive Officer
  Catalyst Pharmaceutical Partners, Inc.

"Like other of their clients, I have had the pleasure of working with Rx Communications through my tenure at two different pharmaceutical companies, through IPO’s, drug trials and product launches.  Staffed only with senior level counselors, Rx has an unparalleled wealth of life science industry experience and an ability to truly understand key market drivers in order to properly position the company and attract the right investors, analysts and press, to the story.  Their clients stick with them, because the firm delivers. Their track record speaks for itself."

• Jim Meer, Former Senior Vice President and Chief Financial Officer of Columbia Laboratories, Inc. and Treasurer of Schein Pharmaceutical, Inc.

"Rx Communications Group has proven itself to us, time and time again, providing a solid blend of analytic, valuation and communication outreach.  As an example, their seamless execution of our investor relations program resulted in a doubling of our trading volume and tripling of our stock price within a period of just nine months. Their work has, and continues to be instrumental to the execution of our corporate growth goals."

• Nancy Lurker
  Chief Executive Officer of PDI, Inc.

"Rx Communications’ deep understanding of the health care and financial markets, coupled with a keen attention to detail and ability to bring fresh ideas to the table, is only part of why I have chosen to work with the firm for more than 10 years; first at 3-Dimensional Pharmaceuticals, until its sale to Johnson & Johnson, and now entrusting our IR and financial media communications to them at TetraLogic. They are a pleasure to work with and I am delighted to have them as part of our team."

• John M. Gill, Founder, President, Chief Executive Officer and Director
  TetraLogic Pharmaceuticals